GU

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Neurology, University of Pennsylvania, Sarcoma, Cardiology, Ivy League, Protocol, University, Rheumatology, Dermatology, Infection, Harvard University, FSD, Melanoma, CMO, Vaccine, FDA, GU, Women's health, Yale University, Pharmaceutical industry

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).

Key Points: 
  • MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).
  • “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams.
  • “Dr.

UroToday and PRIMR Announce Strategic Partnership to Enhance Clinical Trial Awareness

Retrieved on: 
Tuesday, March 5, 2024
Clinical trial, News, Knowledge, Urology, PRIMR, Patient, Organization, Education, Communication, GU, Partnership, Nursing

RENO, Nev., March 5, 2024 /PRNewswire/ -- UroToday, the premier global hub for urology news and education, and PRIMR, a pioneering oncology clinical trial patient education company, proudly announce their inaugural strategic partnership. This groundbreaking collaboration is set to redefine clinical trial awareness and education, marking a historic milestone for both organizations.

Key Points: 
  • RENO, Nev., March 5, 2024 /PRNewswire/ -- UroToday, the premier global hub for urology news and education, and PRIMR, a pioneering oncology clinical trial patient education company, proudly announce their inaugural strategic partnership.
  • This groundbreaking collaboration is set to redefine clinical trial awareness and education, marking a historic milestone for both organizations.
  • In a synergistic move, PRIMR, a trailblazer in doctor-created educational content, has joined forces to revolutionize the dissemination of clinical trial information.
  • This groundbreaking partnership represents a significant leap forward in advancing patient education and elevating clinical trial awareness within the oncology community.

Players Can Now Take Award-Winning Tactical Card Game Gods Unchained On-the-Go with the Global Mobile Release

Retrieved on: 
Thursday, February 29, 2024
GU, App Store (iOS/iPadOS), Epic Games Store, IOS, Growth, Availability, Publishing, Destiny, System, Monolithic kernel, Blog, Immutable object, Google Play, Season, Apple, Arena, Digital collectible card game, Video game

SYDNEY, Feb. 29, 2024 /PRNewswire/ -- Immutable Games, a global leader in web3 game development and publishing, today announced that it is bringing the dynamic landscape and digital ownership of its flagship title, Gods Unchained (GU), to mobile devices around the world. Starting today, the mobile companion app will debut on Google Play and Apple's App Store with a suite of features, providing uninterrupted access to the rich fantasy realm of Eucos, where gods, mortals, and magic hang in the balance of players' fingertips.

Key Points: 
  • Demand and feedback from the pre-alpha build showed the Immutable Games team that the Gods Unchained community wanted to play on the go.
  • With mobile gaming predicted to increase by 4% year-over-year to $111.4 billion in 2024, Gods Unchained is uniquely positioned to capitalize on this trend.
  • "With the mobile gaming industry poised for significant growth in 2024, now is an exciting time to launch GU Mobile.
  • Gods Unchained Mobile companion app can be downloaded now on Google Play and Apple's App Store.

GU Collaboration Collection with The New York Botanical Garden

Retrieved on: 
Tuesday, February 20, 2024
Flower, Horticulture, Education, Collection, New York Botanical Garden, Pajamas, Tree, NYBG, Research, GU, Nightclub

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- GU, the Japanese apparel retailer with the brand theme "TOKYO TO SOHO", announces the launch of its first collection of collaboration items with The New York Botanical Garden (NYBG), one of the world's premier botanical gardens. Items will be available at the GU store in Soho, New York from Friday, February 23rd.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- GU, the Japanese apparel retailer with the brand theme "TOKYO TO SOHO", announces the launch of its first collection of collaboration items with The New York Botanical Garden (NYBG), one of the world's premier botanical gardens.
  • Items will be available at the GU store in Soho, New York from Friday, February 23rd.
  • A portion of the proceeds from GU's collaboration with NYBG supports the Garden's work in plant research and conservation, horticulture, and education.
  • To celebrate the collection launch, the first ten customers who purchase more than $75 in-store, including at least one piece from the botanical-inspired collection, will receive a free one-year, dual membership to The New York Botanical Garden.

GU to Launch New "GU x UNDERCOVER" Collection

Retrieved on: 
Thursday, February 15, 2024
Collection, GU, FREEDOM, Creature, Thought, All rights reserved, UNIVERSAL, Universal Pictures, Taste, Shoe, Black Lagoon, Music, Nightclub

NEW YORK, Feb. 15, 2024 /PRNewswire/ -- GU, the Japanese apparel retailer with the brand theme "TOKYO TO SOHO", announces the launch of its third collaboration collection with UNDERCOVER, the leading Japanese fashion brand with an unmatched presence. Items will be available at the GU store in Soho, New York from Friday, March 22nd.

Key Points: 
  • Items will be available at the GU store in Soho, New York from Friday, March 22nd.
  • Starting from the keyword "KOZMIK/NOISE," the approach for this collection is to take items that at first glance seem basic and alter their look and how they're worn.
  • The collection also includes "triple collaboration" items featuring graphics from the UNIVERSAL MONSTERS* characters such as Frankenstein and Creature from the Black Lagoon.
  • I hope that this collaboration will be an opportunity for people of all generations and regions to learn more about UNDERCOVER and GU."

Trial mining license at Coringa renewed for a further three years

Retrieved on: 
Wednesday, January 31, 2024
AIM, GU, ANM, FY, News, TSX, Mining, SRB, Gold, Rare-earth element

Trial mining license at Coringa renewed for a further three years.

Key Points: 
  • Trial mining license at Coringa renewed for a further three years.
  • Serabi Gold plc (“Serabi” or the “Company”) (AIM: SRB, TSX: SBI), is pleased to announce a three year renewal of the trial mining licence for its wholly owned Coringa mine (“Coringa”).
  • The National Mining Agency (ANM) has issued a renewal of the Company’s trial mining licence (“GU") for Coringa for an additional three years, demonstrating continued stakeholder support for Coringa.
  • The GU permits the transport of up to 50,000 tonnes of ore per annum from Coringa, to be processed at the Palito Complex.

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Retrieved on: 
Friday, January 26, 2024
MMAE, Neoplasm, Patient, PST, Yale school, CSPC, Shijiazhuang Pharma Group, Yale School of Medicine, ADC, Rash, Peripheral neuropathy, Brentuximab vedotin, ASCO, MUC, Poster, Society, Cervical cancer, Safety, EV, GU, Corbus, Urology, Tab, Trial of the century, Pharmaceutical industry

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.

Key Points: 
  • The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.
  • The poster will also be available on the Corbus website at the start of the poster presentation.
  • We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."
  • Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

Retrieved on: 
Monday, January 22, 2024
ASX, Patient, Prostate cancer, ASCO, Society, Immunotherapy, Renal cell carcinoma, PSMA, GU, Kidney cancer, Prostate, TLX

MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.

Key Points: 
  • MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.
  • Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for prostate and kidney cancer at ASCO GU 2024, the leading specialised event for GU cancer care worldwide.
  • “The ProstACT GLOBAL study of TLX591 (177Lu rosopatamab tetraxetan) will be presented, the first Phase III trial to evaluate TLX591, our lead radio-antibody drug conjugate (rADC) therapy candidate in patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC).
  • “Eric Jonasch MD, will present the STARLITE-1 investigator-initiated trial of Telix’s therapy candidate, TLX250 (177Lu girentuximab), in combination with immunotherapy in clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Retrieved on: 
Monday, January 22, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Bristol Myers Squibb, Exelixis, Checkmate, Patient, Progression-free survival, OS, Partnership, RCC, ASCO, Survival, Society, Risk, Metastasis, PFS, Abstract, Safety, Liver, Confidence interval, GU, BMY, Sunitinib, IMDC, Pharmaceutical industry

Superior overall survival (OS) was also observed in patients treated with the combination.

Key Points: 
  • Superior overall survival (OS) was also observed in patients treated with the combination.
  • ORR (secondary endpoint): The combination regimen showed durable response improvements, doubling the ORR compared to sunitinib (55.7% vs. 27.7%, respectively).
  • ORR: In patients with intermediate-/ poor-risk, ORR was more than doubled at 52.6% with Opdivo and CABOMETYX vs. 23.0% with sunitinib.
  • In those with favorable risk profiles, the number of patients who achieved CR was doubled (16.2% vs. 8.3%) with the combination regimen.

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Retrieved on: 
Friday, January 26, 2024
Patient, PST, Prostate cancer, Carcinoma, Bladder cancer, ASCO, Team Impulse, Society, TSC1, Urethra, GU, TSC2, Progress, Kidney cancer, Cancer

LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.

Key Points: 
  • LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    Date/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST
    In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer
    Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study.
  • Session Title: Trials in Progress Poster Session C: Renal Cell Cancer: Adrenal, Penile, Urethral and Testicular Cancers
    Date/Time: January 27, 2024 – 7:00 – 8:00 am; 11:30 am – 1:00 pm PST